Company / Depreciation & Amortization
Dianthus Therapeutics, Inc. /DE/ Depreciation & Amortization History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$67.0K
FY2024
5-year range
$30.0K / $2.0M
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
#157 of 163
Health Care
What the data says
Among 163 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the top 4% for depreciation & amortization. Increased from $30,000 to $67,000 over the past 2 years.
Based on SEC 10-K filings.
$67,000 in FY2024 with a 5-year CAGR of -48.5%.
Increased from $30,000 to $67,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -67.9%
- 5-Year CAGR
- -48.5%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 163This company $67.0K Sector average $219.4M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -48.5%, indicating a declining trend.
- In FY2024, depreciation & amortization increased 0.0% year-over-year.
- Ranks #157 out of 163 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $67.0K | +0.0% |
| FY2023 | $67.0K | +123.3% |
| FY2022 | $30.0K | -98.5% |
| FY2021 | $2.0M | +2.1% |
| FY2020 | $2.0M | +7.3% |
| FY2019 | $1.8M | +110.6% |
| FY2018 | $875.0K | +132.7% |
| FY2017 | $376.0K | +6166.7% |
| FY2016 | $6.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026